Multiple Myeloma Clinical Trials & Research

MSK is a major research institution. During your treatment for multiple myeloma, your care team may ask if you want to join a clinical trial.

What is a clinical trial?

Clinical trials are research studies that test new treatments, procedures, or devices to see how well they work. They are an important part of helping to prevent, treat, and cure cancer. Almost every cancer treatment given to patients was first tested during a clinical trial.

MSK tests new treatments for multiple myeloma. In general, treatment trials test new drugs, drug combinations, devices, and ways of doing procedures, surgery, or radiation therapy.

Sometimes a clinical trial gives you access to new therapies that are not yet available at most hospitals. Talk with your doctor about whether joining a clinical trial is right for you.

Clinical trials are designed to answer questions about:

  • Safety
  • Benefits
  • Side effects
  • Whether some people are helped more than others

MSK will start a clinical trial only if our researchers think we can improve methods for cancer:

  • Prevention
  • Treatment
  • Diagnosis
  • Screening

For more information, please read Clinical Trials at MSK: What You Need to Know.

Clinical trials to improve treatments for multiple myeloma

MSK is researching new ways to evaluate people with myeloma just when they’re diagnosed. We aim to evaluate how they may respond to treatment.

MSK researchers are learning more about the genetics of multiple myeloma. We are using this knowledge to find better drugs to control the disease.

We look for changes (mutations and variants) that can make the cancer worse. MSK has a team of experts in using diagnostic tools, such as DNA sequencing or microarray analysis. A microarray is a lab tool that can analyze thousands of genes at one time. 

Through MSK clinical trials, we’re exploring the best ways to combine standard chemotherapy drugs with immune-modifying drugs. We also are testing newer immunotherapies and mechanisms of action (how a drug affects the body).

You can search below for the latest list of MSK’s clinical trials for multiple myeloma and related plasma cell diseases.

and/or
37 Clinical Trials found
A Study of Music Therapy for Blood Cancer Survivors with Cognitive Difficulties
Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of Talquetamab for People With Multiple Myeloma Who Had CAR T Cell Therapy
Researchers want to see if the drug talquetamab is useful for treating multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment. They also recently received a CAR T cell therapy called idecabtagene autoleucel.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
With CAR T-cell therapy, some of a patient's own T cells (a type of white blood cell) are removed and genetically modified in a laboratory to recognize their own cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body. This approach is a form of immunotherapy.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
Phase 2 Study of Different Sequences of Cilta-cel CAR T-Cell Therapy Plus Talquetamab, Daratumumab, and Other Medications, With or Without Teclistamab, in People With Newly Diagnosed Multiple Myeloma
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient's stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient's immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
New York City
Smoldering Myeloma Registration Trial (SMRT Study)
The purpose of this research study is to understand more about smoldering multiple myeloma (SMM). SMM is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms. 
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau